1. Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection 
Sanford Chodosh 
Clinical Microbiology and Infection 
Volume 4, Pages S25-S31 (March 1998)
DOI: /j tb00686.x
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Clinical success rates with grepafloxacin versus comparator drugs in CAP at 3-5 days post-treatment in the clinically evaluable population.
Clinical Microbiology and Infection 1998 4, S25-S31DOI: ( /j tb00686.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Clinical success rates with grepafloxacin versus comparator drugs in CAP at days post-treatment in the clinically evaluable population.
Clinical Microbiology and Infection 1998 4, S25-S31DOI: ( /j tb00686.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Clinical success rates with grepafloxacin versus comparator drugs in CAP at days post-treatment in the microbiologically and clinically evaluable population.
Clinical Microbiology and Infection 1998 4, S25-S31DOI: ( /j tb00686.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

5. Figure 4
Eradication of Haemophilus influenzae with grepafloxacin versus comparator drugs at 3-5 days post-treatment in the microbiological intent-to-treat population.
Clinical Microbiology and Infection 1998 4, S25-S31DOI: ( /j tb00686.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

6. Figure 5
Eradication of Moraxella catarrhalis with grepafloxacin versus comparator drugs at 3-5 days post-treatment in the microbiological intent-to-treat population.
Clinical Microbiology and Infection 1998 4, S25-S31DOI: ( /j tb00686.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions